What is Sight Diagnostics?
Sight Diagnostics operates at the intersection of artificial intelligence and hematology, providing a sophisticated platform designed to revolutionize blood analysis and infectious disease diagnostics. The company's core technology focuses on the digitization of blood samples, allowing for high-precision results that were previously confined to centralized laboratory environments. By streamlining the diagnostic workflow, Sight Diagnostics empowers healthcare providers to make informed, real-time clinical decisions, thereby enhancing patient outcomes and operational efficiency in diverse medical settings. Their market position is defined by a commitment to replacing cumbersome, legacy diagnostic hardware with agile, AI-powered solutions that meet the demands of modern, decentralized healthcare systems.
How much funding has Sight Diagnostics raised?
Sight Diagnostics has raised a total of $145.8M across 5 funding rounds:
Series A
$6M
Series B
$16M
Other Financing Round
$25M
Series C
$27.8M
Series D
$71M
Series A (2014): $6M with participation from Innovation Endeavors, OurCrowd, Emery Capital, and Clal Biotechnology Industries
Series B (2016): $16M led by OurCrowd, New Alliance Capital, and GEOC
Other Financing Round (2018): $25M supported by Innovation Endeavors
Series C (2019): $27.8M featuring Longliv Ventures
Series D (2020): $71M, investors not publicly disclosed
Key Investors in Sight Diagnostics
Longliv Ventures
Longliv Ventures is a strategic investment arm of the CK Hutchison Holdings Group, focusing on health and lifestyle challenges through innovative digital health solutions.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in transformational technologies and emergent ecosystems, leveraging data and advanced engineering to disrupt life sciences.
OurCrowd
OurCrowd is a global venture investment platform that provides accredited investors with access to startups and institutional-grade technology opportunities.
What's next for Sight Diagnostics?
With the successful completion of its latest funding round, Sight Diagnostics is well-positioned to accelerate its global commercialization strategy and expand its diagnostic capabilities. The company is expected to leverage this capital to scale its manufacturing operations and deepen its penetration into international markets, particularly where point-of-care testing is critical. As the healthcare industry continues to prioritize decentralized care models, Sight Diagnostics' ability to provide lab-grade results at the bedside will likely serve as a primary growth catalyst. Future strategic initiatives will likely focus on integrating additional diagnostic assays into their platform, further cementing their role as a foundational player in the digital health ecosystem.
See full Sight Diagnostics company page
